Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 15:10:733-743.
doi: 10.2147/JHC.S409011. eCollection 2023.

Clinical Results, Risk Factors, and Future Directions of Ultrasound-Guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma

Tian-Tian Dong  1   2   3 , Lan Wang  1   2   3 , Ming Li  1   2   3 , Ci Yin  1   2   3 , Yuan-Yuan Li  1   2   3 , Fang Nie  1   2   3
Affiliations
Review

Clinical Results, Risk Factors, and Future Directions of Ultrasound-Guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma

Tian-Tian Dong et al. J Hepatocell Carcinoma. .

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with a relatively poor prognosis, especially for advanced HCC. With the availability of a variety of treatment options, the treatment strategies for HCC have become more and more diversified. Microwave ablation (MWA) has gradually been considered as a viable alternative to surgical resection (SR) owing to its comparable long-term survival, reduced complications, and greater preservation of hepatic parenchyma. However, clinical outcomes, tumor progression, and recurrence of HCC after MWA remain major concerns. Here, after reviewing the current therapeutic options for HCC, we focus on MWA, describing the advantages and challenges of MWA and the clinical results after treatment. We then focused on prognostic factors that influence post-ablation clinical outcomes and briefly presented the strategy of MWA for future clinical treatment.

Keywords: clinical outcomes; hepatocellular carcinoma; microwave ablation; progression.

PubMed Disclaimer

Conflict of interest statement

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article. The authors report no conflicts of interest in this work.

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660 - DOI - PubMed
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2 - DOI - PubMed
    1. Sugawara Y, Inomata Y. Indications for living donor liver transplantation in patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2016;5(5):429–432. doi:10.21037/hbsn.2016.09.01 - DOI - PMC - PubMed
    1. Simmerman E, Chung J, Lawson A, et al. Application of irreversible electroporation ablation as adjunctive treatment for margin enhancement: safety and efficacy. J Surg Res. 2020;246:260–268. doi:10.1016/j.jss.2019.06.010 - DOI - PubMed
    1. Vitale A, Peck-Radosavljevic M, Giannini EG, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66(2):412–423. doi:10.1016/j.jhep.2016.09.012 - DOI - PubMed